As such, motor complications and non-motor symptoms in PwP remain a challenge in the successful treatment of PD, but substantial preclinical and clinical evidence is becoming available that the use of optimised dopamine-based regimes, as well as compounds targeting non-dopaminergic neurotransmitter and neuropeptide systems, can be useful. This evidence concerns the gene NPS and Parkinson disease.